Navigation Links
Orchid Cellmark to Announce Third Quarter 2008 Financial Results on October 30, 2008
Date:10/24/2008

PRINCETON, N.J., Oct. 24 /PRNewswire-FirstCall/ -- Orchid Cellmark Inc. (Nasdaq: ORCH), a leading worldwide provider of identity DNA testing services, will release its third quarter 2008 financial results on Thursday, October 30, 2008 at approximately 7:00 a.m. EDT, and is hosting a conference call and webcast to discuss the results at 10:00 a.m. EDT on the same day. Management will discuss financial results for the third quarter 2008 as well as operating highlights. A question-and-answer session will follow management's discussion. All interested parties are encouraged to listen to the live conference call or the live or archived webcast.

Conference Call Details

Date and Time: Thursday, October 30, 2008 at 10:00 a.m. EDT

Dial-In: US/Canada: (877) 266-0703

Int'l/Local: (706) 643-7682

Conference ID: 70588526

Webcast: Live webcast and replay available via the Investor Relations section of the company's website at http://www.orchidcellmark.com. The webcast will be available for 90 days.

About Orchid Cellmark

Orchid Cellmark (Nasdaq: ORCH) is a leading international provider of DNA testing services primarily for forensic and family relationship applications. Orchid Cellmark is one of the largest providers of forensic DNA testing services and its DNA results are used by the criminal justice system to assist with the identification of perpetrators, the exclusion of suspects and the exoneration of wrongfully convicted individuals. The company provides DNA family relationship testing to numerous child services organizations and individuals seeking to verify parentage. Orchid Cellmark also serves immigration and security authorities for DNA testing of individuals. In the agriculture field, the company provides DNA testing services for selective trait breeding. Orchid Cellmark's strong market positions in these areas reflect the company's accredited laboratories in the U.S. and U.K., its innovative genetic analysis technologies and expertise, and the company's reputation for exceptional quality, reliability and customer service for nearly two decades. More information on Orchid Cellmark can be found at http://www.orchidcellmark.com.

Contact:

Investors: Media:

Mary Bashore Rick Anderson

Orchid Cellmark Inc. The Torrenzano Group

(609) 750-2324 (212) 681-1700

ir@orchid.com randerson@torrenzano.com


'/>"/>
SOURCE Orchid Cellmark Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Orchid Cellmark Appoints James F. Smith Chief Financial Officer
2. Orchid Cellmark to Announce Third Quarter 2007 Financial Results on November 1, 2007
3. Orchid Cellmark to Purchase ReliaGene Technologies, Inc.
4. Orchid Cellmark Applauds Expansion of Federal Forensic DNA Identity Testing to Include All Arrestees
5. Orchid Cellmark to Announce First Quarter 2008 Financial Results on May 8, 2008
6. Orchid Cellmark Appoints Jeffrey S. Boschwitz as Vice President, North America Marketing & Sales
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
9. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
10. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
11. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/11/2017)... , ... January 11, 2017 , ... Back pain relief ... No Shots and No Surgery for positive back pain relief for WAR members. , ... results worldwide and could be life changing for millions suffering from chronic back pain. ...
(Date:1/11/2017)... , PITTSBURGH and BENGALURU, ... N.V. (NASDAQ, TASE: MYL) and Biocon Ltd. (BSE code: ... and Drug Administration (FDA) has accepted Mylan,s biologics license ... filing through the 351(k) pathway. This product is a ... treat certain HER2-positive breast cancers. The anticipated FDA goal ...
(Date:1/11/2017)... 2017  GenVec, Inc. (NASDAQ: GNVC ... that its chief scientific officer, Douglas E. ... platform for translational development of innovative gene and ... upcoming Phacilitate Cell & Gene Therapy World 2017 ... Dr. Brough,s presentation will highlight the utility of ...
(Date:1/11/2017)... ... January 11, 2017 , ... KBioBox llc ... with Poseida Therapeutics Inc, the San Diego based specialist in gene and cell ... KBioBox in order to harness KBioBox’s powerful BioEngine Algorithms which do not compromise ...
Breaking Biology Technology:
(Date:12/15/2016)... ... Research and Markets has announced the addition of the "Global ... The report forecasts the global military biometrics market to grow at a ... has been prepared based on an in-depth market analysis with inputs from ... over the coming years. The report also includes a discussion of the ...
(Date:12/12/2016)... CLEVELAND , Dec. 12, 2016  Researchers ... commercial possibilities for graphene by combining the material ... a highly sensitive pressure detector able to sense ... of a small spider.  The ... and can be read here:  http://science.sciencemag.org/content/354/6317/1257 ...
(Date:12/7/2016)... TEL AVIV, Israel , December 7, 2016 ... year with the expansion of its patent portfolio, which grew to over ... , , ... led by its recently filed patent entitled " System, Device, ... which covers technology that enables device makers to forego costly hardware components ...
Breaking Biology News(10 mins):